AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read$HRMY

Harmony CEO Jeffrey M. Dayno to Retire; Peter Anastasiou Named Successor

Harmony Biosciences (HRMY) announced CEO Jeffrey M. Dayno will retire and step down from the board on Dec 31, 2026. COO Peter Anastasiou will succeed him as CEO and a Class I director on Jan 1, 2027, as part of a planned leadership transition. Dayno will serve as a non-executive advisor through 2027.

Original reporting
tradingview.com
Published Oct 13, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Harmony CEO Jeffrey M. Dayno to Retire; Peter Anastasiou Named Successor — source image
Source · tradingview.com
Decision brief

The 30-second read

$HRMYNeutralLow
01

Why it matters

The change may affect stock volatility ahead of the transition date, but no immediate financial impact is disclosed.

02

Market read

Exec change is a corporate event that could modestly influence HRMY's share price as investors reassess leadership.

03

What to watch

Anastasiou's prior experience at Capsida and Lundbeck may bring fresh partnerships or licensing deals.

Relevance 7/10Novelty 6/10Timing: effective Jan 1 2027

Background

Harmony Biosciences Holdings filed an 8‑K announcing its leadership succession plan.

Company-level read

Ticker impact

$HRMYNeutralHigh confidence
Context

Harmony Biosciences announced CEO Jeffrey Dayno will retire and COO Peter Anastasiou will become CEO effective Jan 1, 2027.

Expected impact

modest pressure as investors assess the new CEO's track record

Evidence & confidence

First‑report executive change; no immediate financial metrics, but market typically reacts to leadership uncertainty.

Market effects

Sector

Potential ripple in biotech sector as peers may be compared on leadership stability.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global relevance beyond niche biotech community.

Counterpoint

What could challenge this read

New CEO could accelerate pipeline progress, offering upside if execution improves.

Key entities

  • person
    Jeffrey M. Dayno

    Outgoing President and CEO of Harmony Biosciences

  • person
    Peter Anastasiou

    Incoming President and CEO, former COO of Harmony Biosciences

Read at source← All news

StoryHarmony Biosciences announces CEO succession, COO Peter Anastasiou to take helm in 2027

Also covered by

2 outlets

Related articles

OCT 12
$HRMYHigh

Why Harmony Biosciences Stock Got Mashed on Monday

Harmony Biosciences (HRMY) shares fell over 5% after announcing COO Peter Anastasiou will become CEO in 2027, replacing Jeffrey Dayno. The company reaffirmed its full-year revenue guidance for Wakix at $1B-$1.04B and maintained its strategic priorities. Dayno will stay in an advisory role.

finance.yahoo.com2 min
OCT 12
$HRMYMed

Why is Harmony Biosciences stock sliding today?

Harmony Biosciences (HRMY) shares fell 5.2% after announcing CEO succession plans. Current COO Peter Anastasiou will replace Jeffrey M. Dayno in 2027. The company reiterated its 2026 revenue guidance of $1.0B-$1.04B for WAKIX and confirmed pipeline data release timelines. The stock's decline was attributed to market caution around leadership changes and existing investor concerns.

investing.com5 min
OCT 12
$HRMYLow

Harmony Biosciences names Peter Anastasiou as next CEO

Harmony Biosciences (HRMY) named Peter Anastasiou as its next CEO, effective January 1, 2027. He will succeed Jeffrey M. Dayno, who will retire at the end of 2026. Anastasiou is currently the company's COO and previously served on its board. The company reiterated its 2026 revenue guidance of $1.0B to $1.04B for WAKIX. Anastasiou's background includes leadership roles at Capsida Biotherapeutics and Lundbeck.

investing.com2 min
SEP 3
$HRMYHighAI 8/10

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.

finance.yahoo.com2 min